PeptideStack
5.2kquestions
20kanswers
220users

What happens to mazdutide after six weeks at 30 °C in solution?

Asked 30 Apr 2026Modified 2 months agoViewed 1.3k times
4

Details up front: mazdutide · six weeks · 30 °C.

I can predict the outcome but I cannot explain it, which means I will get the next case wrong.

I would like to know how confident the field actually is about this.

Can someone derive this rather than assert it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
shareeditfollowflag
ID
askedines_delacruz16k1630 Apr 2026
3Voting to keep this open — it is more specific than it first looks. – forty_two_c 3 months ago
add a comment

1 Answer

Accepted answer first, then by votes
86

Accepted answer

six weeks is 42 days, which at 30 °C is on the order of 238 refrigerated days. 30 °C is 25 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 5.7 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. In solution the routes that matter are hydrolysis of the backbone, deamidation at Asn, and physical association — the first two cost content, the third costs neither until it precipitates. Over 42 days at 30 °C you should expect all three to have moved, and a purity figure to have noticed only some of them. Reconstituted material has no certificate; the one in the box describes the powder.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Degradation pathway by condition

PathwayDominant whenDetected by
DeamidationSolution, neutral to alkaline pHRP-HPLC, +1 Da on MS
OxidationLight, trace metals, peroxidesRP-HPLC, +16 Da on MS
HydrolysisSolution, extremes of pHRP-HPLC, fragment masses
AggregationAgitation, interfaces, high concentrationSEC, visual haze; often invisible on RP-HPLC
Freeze-concentration damageFreeze-thaw of buffered solutionSEC, loss of recovered content

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Sequence determines which pathways apply, so general statements are general.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
HC
answered · acceptedhaze_check9.3k166 Jun 2026
5The doubling-per-ten-degrees rule is the part I did not know and now use constantly. – lane_transit 3 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.